| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(00)02607-6 |
| P698 | PubMed publication ID | 10968438 |
| P50 | author | David M Koelle | Q40734874 |
| P2093 | author name string | L Corey | |
| M Boeckh | |||
| A P Limaye | |||
| C L Davis | |||
| P2860 | cites work | Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease | Q56902955 |
| Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor‐Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation | Q57181611 | ||
| Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis | Q70466635 | ||
| Treatment of gancyclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation | Q72414070 | ||
| Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation | Q73088167 | ||
| Cytomegalovirus: the taming of the beast? | Q73979945 | ||
| Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood | Q77168082 | ||
| Quantitation of human cytomegalovirus DNA in peripheral blood leukocytes of heart transplant recipients: relationship with pp65 antigenemia and with antiviral therapy | Q77664300 | ||
| Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients | Q33488688 | ||
| Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group | Q33857954 | ||
| Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. | Q35816311 | ||
| Factors influencing detection of quantitative cytomegalovirus antigenemia | Q37073815 | ||
| Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. | Q40650576 | ||
| Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir | Q41649805 | ||
| Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor | Q42554403 | ||
| Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy | Q44745022 | ||
| Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection | Q46154428 | ||
| Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy | Q47713709 | ||
| Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. | Q53346269 | ||
| Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. | Q53356778 | ||
| The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. | Q54071498 | ||
| Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: is emergence of resistance imminent? | Q54132682 | ||
| Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. | Q54138764 | ||
| Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. | Q54145038 | ||
| P433 | issue | 9230 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| P304 | page(s) | 645-649 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. | |
| P478 | volume | 356 |
| Q64121049 | A Practical Review of Cytomegalovirus in Gastroenterology and Hepatology |
| Q46485589 | A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. |
| Q36304783 | Addressing viral resistance through vaccines |
| Q96304910 | Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series |
| Q64241510 | Anticytomegalovirus Peptides Point to New Insights for CMV Entry Mechanisms and the Limitations of Screenings |
| Q35917546 | Antimicrobial prophylaxis in solid-organ transplantation. |
| Q30430427 | Antiviral Drug Resistance of Human Cytomegalovirus |
| Q38370342 | Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients |
| Q28282376 | Antiviral drug resistance: mechanisms and clinical implications |
| Q34992622 | Antiviral prophylaxis and treatment (excluding HIV therapy). |
| Q44723812 | Antiviral treatment after solid organ transplantation. |
| Q33719294 | Aspergillus infections in transplant recipients |
| Q43695978 | Assessment of cytomegalovirus infections using neopterin and a new immunoblot |
| Q34918418 | Beta-herpesvirus challenges in the transplant recipient |
| Q38047084 | Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation |
| Q26768473 | CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients |
| Q43935588 | CMV prophylaxis: what is valid in 2002? |
| Q53032949 | CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. |
| Q26824869 | CMV: Prevention, Diagnosis and Therapy |
| Q34626898 | CNS manifestations of cytomegalovirus infections: diagnosis and treatment |
| Q36006091 | Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report |
| Q40356916 | Central nervous system infectious complications early after liver transplantation. |
| Q40589966 | Characterising variation in five genetic loci of cytomegalovirus during treatment for congenital infection. |
| Q90062938 | Choice of Study Populations for Vaccines |
| Q38067694 | Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients |
| Q44282947 | Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection |
| Q46877359 | Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients |
| Q26826856 | Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation |
| Q43974785 | Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients |
| Q40968263 | Combination therapy for multidrug-resistant cytomegalovirus disease. |
| Q44798179 | Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy |
| Q38359566 | Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay |
| Q42906543 | Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene |
| Q34774333 | Controversies in lung transplantation: management of cytomegalovirus infections |
| Q47577035 | Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient. |
| Q34626941 | Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. |
| Q40183662 | Cytomegaloviral infection in solid organ transplant recipients: preliminary report of one transplant center experience |
| Q34722194 | Cytomegalovirus (CMV) resistance to antivirals |
| Q35842707 | Cytomegalovirus and lung transplantation |
| Q44512615 | Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies |
| Q44461493 | Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. |
| Q34583495 | Cytomegalovirus drug resistance and clinical implications |
| Q33972690 | Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies |
| Q98727032 | Cytomegalovirus infection after liver transplantation |
| Q43869508 | Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients |
| Q38242802 | Cytomegalovirus infection in liver transplant recipients: updates on clinical management |
| Q42250541 | Cytomegalovirus infection in renal transplant recipients: one center's experience |
| Q37098580 | Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives. |
| Q44568280 | Cytomegalovirus infection resistant to ganciclovir in a renal transplant patient |
| Q37359332 | Cytomegalovirus infections in solid organ transplantation: a review |
| Q44190589 | Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients |
| Q44963388 | Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation |
| Q36434411 | Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy |
| Q52640678 | Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. |
| Q35110913 | Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients |
| Q36728782 | Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients |
| Q37680941 | Defining the risks for cytomegalovirus infection and disease after solid organ transplantation |
| Q57167954 | Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials |
| Q44796576 | Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir |
| Q37375243 | Delayed onset CMV disease in solid organ transplant recipients |
| Q46764122 | Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation |
| Q38100041 | Desirability and feasibility of a vaccine against cytomegalovirus |
| Q34975934 | Detection of cytomegalovirus drug resistance mutations by next-generation sequencing |
| Q74409705 | Detection of herpes viruses in clinical samples using real-time PCR |
| Q37346001 | Diagnosis & management of cytomegalovirus infections in the GI tract |
| Q34934423 | Diagnosis and treatment approaches of CMV infections in adult patients |
| Q56974271 | Direct visualisation of cytomegalovirus-specific cd8+ t cells in renal transplant recipients |
| Q35692301 | Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait? |
| Q46733515 | Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival |
| Q40197189 | Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice |
| Q36321541 | Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients |
| Q44800855 | Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients |
| Q44735264 | Efficacy preemptive therapy with ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients |
| Q39953959 | Efficient inhibition of human cytomegalovirus DNA polymerase expression by small hairpin RNA in vitro |
| Q44254747 | Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients |
| Q33981473 | Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. |
| Q40074992 | Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature |
| Q38742523 | Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand. |
| Q35964751 | Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection |
| Q58854031 | Esquemas de prevención de la infección por citomegalovirus: terapia anticipada frente a profilaxis universal |
| Q44955040 | Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. |
| Q40560337 | Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease |
| Q54788946 | FasL-transduced muscular cells induce apoptosis of activated T-lymphocytes. |
| Q34569223 | Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. |
| Q46594274 | Ganciclovir prophylaxis and beta-herpesvirus in renal transplant recipients |
| Q43783687 | Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients |
| Q73176302 | Ganciclovir-resistant cytomegalovirus |
| Q44282953 | Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. |
| Q44000196 | Ganciclovir-resistant cytomegalovirus in organ transplant recipients |
| Q37544353 | Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens |
| Q33338232 | Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q28069489 | How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients |
| Q33592427 | How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients |
| Q38779846 | Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. |
| Q58824913 | Human cytomegalovirus pUL97 drug-resistance mutations in congenitally neonates and HIV-infected, no-drug-treated patients |
| Q24556634 | Human cytomegalovirus resistance to antiviral drugs |
| Q35661046 | Human embryonic stem cells: a potential source for cellular therapy |
| Q35076852 | Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients |
| Q37024817 | Impairment of cytomegalovirus-specific cellular immune response as a risk factor for cytomegalovirus disease in transplant recipients |
| Q34437840 | Improved monitoring of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation by an ultrasensitive plasma DNA PCR assay |
| Q37065216 | Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences |
| Q41496012 | Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis |
| Q40531014 | Infections under immunosuppressive therapy following organ transplantation |
| Q46554298 | Influence of ganciclovir prophylaxis on citomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients |
| Q40706730 | Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline |
| Q39479368 | Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients |
| Q40526580 | Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports |
| Q36043642 | Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence |
| Q37957446 | Leflunomide for cytomegalovirus: bench to bedside |
| Q28294236 | Leflunomide: A Drug with a Potential Beyond Rheumatology |
| Q35573953 | Leflunomide: a treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation |
| Q39325580 | Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent |
| Q37803335 | Management of cytomegalovirus infection in solid organ transplantation |
| Q57456611 | Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study |
| Q37242251 | Maribavir: a novel antiviral agent with activity against cytomegalovirus |
| Q34439235 | Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients |
| Q34464943 | Molecular techniques should not now replace cell culture in diagnostic virology laboratories |
| Q37848137 | Monitoring and managing viral infections in pediatric renal transplant recipients |
| Q62475088 | Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia |
| Q35635817 | Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates |
| Q40745345 | Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system |
| Q37734486 | Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. |
| Q89366245 | New Developments in the Management of Cytomegalovirus Infection After Transplantation |
| Q40348364 | New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure |
| Q35636214 | Novel heparan sulfate-binding peptides for blocking herpesvirus entry. |
| Q37624896 | Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections |
| Q37777434 | Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients |
| Q37488882 | Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir |
| Q38834042 | Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection |
| Q77355153 | Pattern and persistence of the epitope-specific IgM response against human cytomegalovirus in renal transplant patients |
| Q44300481 | Pharmacokinetics of ganciclovir in pediatric renal transplant recipients |
| Q45946480 | Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. |
| Q37247594 | Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir |
| Q24200991 | Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients |
| Q24244606 | Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients |
| Q44249073 | Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients |
| Q53120860 | Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction. |
| Q34785629 | Prevention and management of CMV-related problems after hematopoietic stem cell transplantation |
| Q36777860 | Prevention and management of cytomegalovirus infection in solid-organ transplantation |
| Q34722706 | Prevention and treatment of viral infections in stem cell transplant recipients |
| Q34142019 | Prevention of cytomegalovirus disease in recipients of solid-organ transplants |
| Q36600828 | Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy |
| Q33932079 | Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients |
| Q44441505 | Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients |
| Q34191791 | Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation |
| Q34191785 | Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation |
| Q41500588 | Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients |
| Q46618896 | Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients |
| Q33205085 | Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation |
| Q35740698 | Pulmonary complications of solid organ and hematopoietic stem cell transplantation |
| Q44531827 | Quantitative analysis of CMV DNA in children the first year after liver transplantation |
| Q44355907 | Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation |
| Q48039802 | Rapid detection and quantitation of ganciclovir resistance in cytomegalovirus quasispecies |
| Q41430486 | Rapid detection of human cytomegalovirus UL97 and UL54 mutations directly from patient samples |
| Q44170999 | Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery |
| Q37222032 | Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts |
| Q35845907 | Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo |
| Q44289627 | Recent Advances in the Management of Infections in Liver Transplant Recipients |
| Q38282979 | Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet |
| Q33876672 | Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance |
| Q34666651 | Resistance in viruses other than HIV. |
| Q34756486 | Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms |
| Q38725677 | Resistant cytomegalovirus in intestinal and multivisceral transplant recipients. |
| Q40745646 | Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin |
| Q37127669 | Reuse of a previously transplanted kidney: does success come with a price? |
| Q40262029 | Risk Factors and Outcomes of Ganciclovir Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients |
| Q64923154 | Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. |
| Q90705079 | Risk Factors for the Development of Cytomegalovirus Resistance in Solid Organ Transplantation: A Retrospective Case-Control Study |
| Q24575554 | Role of cell culture for virus detection in the age of technology |
| Q80906275 | Screening of donor and recipient prior to solid organ transplantation |
| Q40745065 | Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients. |
| Q43885849 | Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment |
| Q39478485 | Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing |
| Q38285782 | Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. |
| Q45104485 | Successful allogeneic bone marrow transplantation in a patient with acute myelogenous leukemia and cytomegalovirus retinitis |
| Q86519756 | Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient |
| Q40399325 | Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. |
| Q44438126 | Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro |
| Q42710824 | Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof |
| Q45094234 | The CARI guidelines. CMV disease and kidney transplant: treatment of cytomegalovirus disease in renal transplant recipients |
| Q43438212 | The changing face of invasive aspergillosis in liver transplant recipients |
| Q41836415 | The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein |
| Q37173390 | The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis |
| Q35143349 | The human cytomegalovirus. |
| Q36170937 | The role of the cytomegalovirus antigenemia assay in the detection and prevention of cytomegalovirus syndrome and disease in solid organ transplant recipients: A review of the British Columbia experience |
| Q87425046 | The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation |
| Q37811458 | The search for new therapies for human cytomegalovirus infections. |
| Q26750606 | Traditional and Modern Cell Culture in Virus Diagnosis |
| Q38875887 | Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update |
| Q40426465 | Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients |
| Q57569380 | Trends in Risk Profiles for and Mortality Associated with Invasive Aspergillosis among Liver Transplant Recipients |
| Q37962447 | Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients |
| Q45111047 | Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection |
| Q35592509 | Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago. |
| Q42947488 | Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes |
| Q36694861 | Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. |
| Q46921335 | Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation |
| Q46826218 | Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. |
| Q35917319 | Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts |
| Q79236862 | Varicella inoculation to prevent shingles, and cytomegalovirus inoculation to prevent cytomegalovirus associated graft failures |
| Q37097708 | Viral infection after renal transplantation: surveillance and management |
| Q37721885 | Viral infections in lung transplant recipients |
| Q35962532 | Viral prophylaxis in organ transplant patients |
| Q45421091 | Virus infections post transplant: risk and immunity |
| Q34452529 | Virus population dynamics, fitness variations and the control of viral disease: an update |
| Q81395065 | [Effects of viral infection on transplant recipients] |
| Q81635113 | [Infections after organ transplantation] |
| Q84028040 | [Risk factors for cytomegalovirus in solid organ transplant recipients] |
Search more.